25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

Lyman W. Whitlatch, Michael V. Young, Gary G. Schwartz, John N. Flanagan, Kerry L. Burnstein, Balakrishna L Lokeshwar, Edwin S. Rich, Michael F. Holick, Tai C. Chen

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The hormone 1α,25-dihydroxyvitamin D (1α,25(OH)2D) inhibits growth and induces differentiation of prostate cells. The enzyme responsible for 1α,25(OH)2D synthesis, 25-hydroxyvitamin D (25(OH)D)-1α-hydroxylase (1α-OHase), has been demonstrated in human prostate cells. We compared the levels of 1α-OHase activity in prostate cancer cell lines, LNCaP, DU145 and PC-3 and in primary cultures of normal, cancerous and benign prostatic hyperplasia (BPH) prostate cells. We observed a marked decrease in 1α-OHase activity in prostate cancer cells, including an undetectable level of activity in LNCaP cells. Transient or stable transfection of 1α-OHase cDNA into LNCaP cells increased 1α-OHase activity from undetectable to 4.95pmole/mg±0.69pmole/mg and 5.8pmole/mg±0.7pmole/mg protein per hour, respectively. In response to 25(OH)D, the prohormone of 1α,25(OH)2D, the transfected LNCaP cells showed a significant inhibition of 3H-thymidine incorporation (37%±6% and 56%±4% at 10-8M for transiently and stably transfected cells, respectively). These findings support an important autocrine role for 1α,25(OH)2D in the prostate and suggest that the re-introduction of the 1α-OHase gene to prostate cancer cells, in conjunction with the systemic administration of 25(OH)D, constitutes an endocrine form of gene therapy that may be less toxic than the systemic administration of 1α,25(OH)2D.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume81
Issue number2
DOIs
StatePublished - Aug 23 2002
Externally publishedYes

Fingerprint

Gene transfer
Mixed Function Oxygenases
Prostatic Neoplasms
Cells
Genes
Prostate
Gene therapy
Poisons
Thymidine
Complementary DNA
Hormones
Enzymes
25-hydroxyvitamin D
Prostatic Hyperplasia
Proteins
Genetic Therapy
Transfection
Cell Differentiation
Cell Line

Keywords

  • Cell culture
  • Cytochrome P-450
  • LNCaP
  • Vitamin D

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. / Whitlatch, Lyman W.; Young, Michael V.; Schwartz, Gary G.; Flanagan, John N.; Burnstein, Kerry L.; Lokeshwar, Balakrishna L; Rich, Edwin S.; Holick, Michael F.; Chen, Tai C.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 81, No. 2, 23.08.2002, p. 135-140.

Research output: Contribution to journalArticle

Whitlatch, Lyman W. ; Young, Michael V. ; Schwartz, Gary G. ; Flanagan, John N. ; Burnstein, Kerry L. ; Lokeshwar, Balakrishna L ; Rich, Edwin S. ; Holick, Michael F. ; Chen, Tai C. / 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. In: Journal of Steroid Biochemistry and Molecular Biology. 2002 ; Vol. 81, No. 2. pp. 135-140.
@article{377fdbc8839e4283996d54d2c92d3b4e,
title = "25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer",
abstract = "The hormone 1α,25-dihydroxyvitamin D (1α,25(OH)2D) inhibits growth and induces differentiation of prostate cells. The enzyme responsible for 1α,25(OH)2D synthesis, 25-hydroxyvitamin D (25(OH)D)-1α-hydroxylase (1α-OHase), has been demonstrated in human prostate cells. We compared the levels of 1α-OHase activity in prostate cancer cell lines, LNCaP, DU145 and PC-3 and in primary cultures of normal, cancerous and benign prostatic hyperplasia (BPH) prostate cells. We observed a marked decrease in 1α-OHase activity in prostate cancer cells, including an undetectable level of activity in LNCaP cells. Transient or stable transfection of 1α-OHase cDNA into LNCaP cells increased 1α-OHase activity from undetectable to 4.95pmole/mg±0.69pmole/mg and 5.8pmole/mg±0.7pmole/mg protein per hour, respectively. In response to 25(OH)D, the prohormone of 1α,25(OH)2D, the transfected LNCaP cells showed a significant inhibition of 3H-thymidine incorporation (37{\%}±6{\%} and 56{\%}±4{\%} at 10-8M for transiently and stably transfected cells, respectively). These findings support an important autocrine role for 1α,25(OH)2D in the prostate and suggest that the re-introduction of the 1α-OHase gene to prostate cancer cells, in conjunction with the systemic administration of 25(OH)D, constitutes an endocrine form of gene therapy that may be less toxic than the systemic administration of 1α,25(OH)2D.",
keywords = "Cell culture, Cytochrome P-450, LNCaP, Vitamin D",
author = "Whitlatch, {Lyman W.} and Young, {Michael V.} and Schwartz, {Gary G.} and Flanagan, {John N.} and Burnstein, {Kerry L.} and Lokeshwar, {Balakrishna L} and Rich, {Edwin S.} and Holick, {Michael F.} and Chen, {Tai C.}",
year = "2002",
month = "8",
day = "23",
doi = "10.1016/S0960-0760(02)00053-5",
language = "English (US)",
volume = "81",
pages = "135--140",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

AU - Whitlatch, Lyman W.

AU - Young, Michael V.

AU - Schwartz, Gary G.

AU - Flanagan, John N.

AU - Burnstein, Kerry L.

AU - Lokeshwar, Balakrishna L

AU - Rich, Edwin S.

AU - Holick, Michael F.

AU - Chen, Tai C.

PY - 2002/8/23

Y1 - 2002/8/23

N2 - The hormone 1α,25-dihydroxyvitamin D (1α,25(OH)2D) inhibits growth and induces differentiation of prostate cells. The enzyme responsible for 1α,25(OH)2D synthesis, 25-hydroxyvitamin D (25(OH)D)-1α-hydroxylase (1α-OHase), has been demonstrated in human prostate cells. We compared the levels of 1α-OHase activity in prostate cancer cell lines, LNCaP, DU145 and PC-3 and in primary cultures of normal, cancerous and benign prostatic hyperplasia (BPH) prostate cells. We observed a marked decrease in 1α-OHase activity in prostate cancer cells, including an undetectable level of activity in LNCaP cells. Transient or stable transfection of 1α-OHase cDNA into LNCaP cells increased 1α-OHase activity from undetectable to 4.95pmole/mg±0.69pmole/mg and 5.8pmole/mg±0.7pmole/mg protein per hour, respectively. In response to 25(OH)D, the prohormone of 1α,25(OH)2D, the transfected LNCaP cells showed a significant inhibition of 3H-thymidine incorporation (37%±6% and 56%±4% at 10-8M for transiently and stably transfected cells, respectively). These findings support an important autocrine role for 1α,25(OH)2D in the prostate and suggest that the re-introduction of the 1α-OHase gene to prostate cancer cells, in conjunction with the systemic administration of 25(OH)D, constitutes an endocrine form of gene therapy that may be less toxic than the systemic administration of 1α,25(OH)2D.

AB - The hormone 1α,25-dihydroxyvitamin D (1α,25(OH)2D) inhibits growth and induces differentiation of prostate cells. The enzyme responsible for 1α,25(OH)2D synthesis, 25-hydroxyvitamin D (25(OH)D)-1α-hydroxylase (1α-OHase), has been demonstrated in human prostate cells. We compared the levels of 1α-OHase activity in prostate cancer cell lines, LNCaP, DU145 and PC-3 and in primary cultures of normal, cancerous and benign prostatic hyperplasia (BPH) prostate cells. We observed a marked decrease in 1α-OHase activity in prostate cancer cells, including an undetectable level of activity in LNCaP cells. Transient or stable transfection of 1α-OHase cDNA into LNCaP cells increased 1α-OHase activity from undetectable to 4.95pmole/mg±0.69pmole/mg and 5.8pmole/mg±0.7pmole/mg protein per hour, respectively. In response to 25(OH)D, the prohormone of 1α,25(OH)2D, the transfected LNCaP cells showed a significant inhibition of 3H-thymidine incorporation (37%±6% and 56%±4% at 10-8M for transiently and stably transfected cells, respectively). These findings support an important autocrine role for 1α,25(OH)2D in the prostate and suggest that the re-introduction of the 1α-OHase gene to prostate cancer cells, in conjunction with the systemic administration of 25(OH)D, constitutes an endocrine form of gene therapy that may be less toxic than the systemic administration of 1α,25(OH)2D.

KW - Cell culture

KW - Cytochrome P-450

KW - LNCaP

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=0036345365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036345365&partnerID=8YFLogxK

U2 - 10.1016/S0960-0760(02)00053-5

DO - 10.1016/S0960-0760(02)00053-5

M3 - Article

C2 - 12137802

AN - SCOPUS:0036345365

VL - 81

SP - 135

EP - 140

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 2

ER -